We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Tissue Implant as Alternative to Gene Therapy

By Biotechdaily staff writers
Posted on 15 Jul 2002
Using a patient's own tissue as the site of production and delivery of precise amounts of protein is a new alternative to gene therapy and other protein injections. More...


A tiny strip of skin is taken from the patient and then genetically engineered in vitro by the introduction of specific genes via viral vectors. The small bit of tissue is transformed into a "factory”, called Biopump, which will produce a therapeutic protein for the treatment of diseases such as anemia, muscle wasting, hepatitis and other disorders. After being implanted under the skin, this modified tissue begins to deliver a measured supply of protein. Protein production can last for many months, and the therapy can be safely and immediately stopped by simply removing the implant.

"Biopump is intended as an alternative to intravenous protein injections, gene therapy and slow-release protein technologies,” said Dr. Andrew Pearlman, CEO of Medgenics, the developer of Biopump. "Injections are an inefficient way to deliver therapeutic proteins because there is an initial spike in the concentration of the proteins created at the time of intravenous injection, which can result in toxic side effects. Conversely, there is a rapid decline in protein concentration to levels that are suboptimal in therapeutic terms, and the patient must wait until the next injection until the level of therapeutic protein can be restored.”

The shape of the tissue strip is critical to the BioPump method. It has been selected to allow the tissue to live outside of the body for up to several months while it is being altered genetically. It is substantial enough to comprise a viable tissue but sufficiently thin so that all cells are close enough to the support medium to receive nutrients through diffusion. Only minimal medium is needed and there is no use of animal by-products or serum.

"This is a critical advantage over gene therapy, which is an attempt to produce a drug inside the body by injecting a virus with a desired gene that will initiate the production of a certain protein by body cells. However, it cannot be known how much protein will be produced by protein therapy or from which cells, and there is no practical way to halt gene therapy if needed,” explained Dr. Pearlman. "If you want our treatment to stop, you simply pull it out,” said Dr. Pearlman.




Related Links:
Medigenics

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
HPV Test
Allplex HPV28 Detection
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.